We are a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies.


Kite Pharma

JVC Investment Partners

LG Technology Ventures

Solasta Ventures

Samsara BioCapital

Novo Holdings

Adage Capital Management

Asymmetry Ventures

CaaS Capital Management

Cambrian Biopharma

CAM Capital

Clough Capital Partners

Soleus Capital

SR One

Surveyor Capital

Suvretta Capital Management

Takeda Ventures

Terra Magnum Capital Partners (""""TMCP"""")""

Arcellx

Biotechnology company focused on immunotherapy research and development

2seventy Bio

Biotechnology company specializing in genome editing and cell therapy

Caribou

Biotechnology company focused on gene editing and cell therapy

Precision BioSciences

Pharmaceutical company with a focus on developing therapies for various diseases including cancer and autoimmune conditions

Abbvie

Biotechnology company known for its innovative therapies in oncology and immunology

Amgen

Pharmaceutical company focusing on cancer, cardiovascular, and immunology therapies

Bristol Myers Squibb

Global pharmaceutical company with a diverse portfolio of pharmaceuticals, vaccines, and consumer healthcare products

GlaxoSmithKline

Multinational corporation with a focus on pharmaceuticals, medical devices, and consumer goods

Johnson & Johnson

Global pharmaceutical company known for its innovative medicines and vaccines

Pfizer

Global healthcare company with a focus on innovative pharmaceuticals, eye care, and generic medicines

Novartis

Arcellx, Inc. is a biotechnology company focused on developing innovative immunotherapies for patients with cancer and other incurable diseases. The company's lead products include anitocabtagene autoleucel and ACLX-001, both of which are in clinical trials for the treatment of multiple myeloma and other related conditions.

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.

Arcellx, Inc.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Mar 8, 2024 7:42 AM	e204c9c3
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 8, 2024 7:42 AM	3029c53b
company summary	general
signals	general	Mar 8, 2024 7:42 AM	205565b9
crunchbase trigger	general	Nov 27, 2024 12:50 PM	d0e9ec4a
crunchbase profile	general	Nov 27, 2024 2:23 PM	61b6cecb
li profile	general	Mar 8, 2024 7:42 AM	e73171cd
translate crunchbase fundingrounds	general
peers	general	Mar 8, 2024 7:42 AM	2fbfb474
news basic	general	Mar 8, 2024 7:42 AM	16e98336
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:ARCELLX

Arcellx, Inc.

Last Close

87.22

22/11 21:00

Market Cap

3.07B

Beta: -

Volume Today

342.91K

Avg: -